



KNOWLEDGE SHARING AND CAPACITY BUILDING

- Start early. *Try multiple approaches*, especially if your product is complex. *Focus on complimentary assays*, not redundant assays.
- Obtain early regulatory input, and grow the agency's understanding with your understanding.
- Gradual maturation of potency strategy is possible.
- There still isn't an agreement on where in the cascade to stop
 assessing the potency of a drug. If you can, start with the end in
 mind and develop a functional potency assay.
- Industry and regulators should continue working together to provide general guidance on how to balance the need for a QC-friendly assay and a functional assay.

CGTP Summit 2025 BY THE NUMBERS



First-Time
Attendees

77



Regulators Participated

6



Companies Represented

63



Countries Collaborated

12

Austria | Belgium | Canada | Denmark | France | Japan | Netherlands | Saudi Arabia | South Korea | Sweden | United Kingdom | United States

CASSS RESOURCES

Looking for more past meeting content?

Speaker slides, roundtable notes, and video presentations can be accessed through **Papers and Presentations** and **CASSS On Demand** on our website. **www.casss.org**



